Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0161

Scientific exchange · Dr. Liam Quinn

16 Mar 2026 · In person · Dr. Liam Quinn, Institut Curie · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0161—

Capture insight from this engagement

Location: Institut Curie
Therapeutic area: Nephrology
Country: France
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

eGFR slope interpretation
Patient-reported outcomes

Scientific content used

APRIL-IgAN Phase III topline

Questions raised

How does proteinuria reduction at 9 months translate to eGFR benefit?
Is there any data on APRIL inhibition in FSGS?

Notes

Scientific exchange with academic nephrologist at Institut Curie. Discussed egfr slope interpretation, patient-reported outcomes.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 5
Depth of exchange: 5
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0161

Audit history (0)

All create, update and approval events for this record

No audit events in sample data